The effectiveness of Epidermal Growth Factor Receptor (EGFR)-specific tyrosine kinase inhibitors in NSCLC is associated with mutations in EGFR gene, that is, deletions of the 19–21st exons and amplifications of EGFR gene positively correlate with the clinical benefit of treatment [20]. Here, EGFR is linked to non-small cell lung carcinoma.